counterion is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical checks can detect changes in a reconstituted stock over time. Reverse-phase high-performance liquid chromatography can show loss of main peak, new impurity peaks, or altered retention. Mass spectrometry confirms molecular identity and can reveal modifications. Visual inspection for particles, color change, or turbidity provides a simple first check. If a solution shows signs of degradation or contamination, it is typically discarded rather than re-purified in a routine laboratory.
Once a peptide is dissolved, its solution is generally less stable than the dry powder. Chemical pathways such as hydrolysis, oxidation, and deamidation can alter the molecule, while physical processes can form aggregates or cause adsorption to container walls. The rate depends on pH, buffer composition, temperature, concentration, and the specific sequence. Aqueous stocks are therefore kept cold and used within a defined period. Stability testing is usually performed for each peptide rather than assumed from a general rule.
During reconstitution, solvent penetrates the dry cake and breaks intermolecular contacts that held the peptide in solid form. Dissolution occurs as individual peptide molecules become surrounded by solvent. Hydrophobic regions can associate with one another instead of dissolving, which may produce turbidity or aggregates. pH and ionic strength influence the charge state of ionizable groups and therefore solubility. Buffer salts can help maintain a stable pH, but they can also participate in interactions that affect the final solution.
The concentration of a reconstituted peptide is calculated from the mass of peptide powder and the volume of solvent added. This calculation assumes the powder contains only peptide, but many preparations include counterions, water, or salts. Analytical methods such as ultraviolet absorbance or amino acid analysis can estimate actual peptide content. The relationship between nominal and actual concentration is an area where measurements matter. Open questions remain about how aggregation changes the effective concentration in solution.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (reconstituted) | -20 °C to -80 °C | Exact condition depends on peptide, solvent, and stability data |
| Freeze-thaw stability | Limited number of cycles | Repeated cycles can increase aggregation and precipitation |
| Common degradation pathways | Hydrolysis, oxidation, deamidation | Relative rates depend on sequence, pH, and buffer |
| Container material | Low-binding polypropylene | Reduces adsorption loss for some peptides |
| Analytical method for stability | Reverse-phase HPLC | Monitors main peak loss and formation of impurity peaks |
Quality records typically include a certificate of analysis, batch number, molecular weight, purity result, and recommended storage conditions. After reconstitution, a laboratory log may record solvent, final volume, date, and storage location. Such documentation supports reproducibility and allows later investigation if a preparation behaves unexpectedly. Stability studies often examine purity and concentration over time under defined temperatures, but results are not universally transferable between peptides or formulations. Open questions remain about how best to predict aggregation for specific sequences and how much analytical testing is sufficient for routine laboratory work.
After a peptide is reconstituted, analytical checks can confirm identity, concentration, and purity. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry provides a mass value that supports sequence identity, while ultraviolet absorbance at 214 or 280 nanometers is often used for concentration estimation when the extinction coefficient is known. These methods answer different questions and are complementary. A single measurement rarely establishes full quality, because the same sample can appear acceptable by one method and fail another.
Dissolution involves hydration of polar and charged groups, disruption of intermolecular interactions in the lyophilized powder, and transition to a thermodynamically favored solution state. Not all powder dissolves readily; aggregation, incomplete lyophilization, or high molecular weight can slow reconstitution. The resulting solution may contain particulates or oligomers that affect downstream measurements. Researchers often verify complete dissolution by visual inspection and spectrophotometric or chromatographic methods. The relationship between reconstitution conditions and long-term stability remains an active area of study.
Peptide reconstitution is the process of dissolving a lyophilized peptide powder in a liquid solvent to produce a solution of defined concentration. Lyophilization removes water under vacuum from a frozen peptide solution, leaving a porous cake or powder. The dry form is often more stable for shipping and storage. Reconstitution restores the peptide to a liquid state for analytical, biochemical, or formulation work. The exact solvent depends on peptide sequence and intended assay.
Practical handling often includes dividing a reconstituted solution into single-use aliquots to limit freeze-thaw cycling. Vials made of low-binding plastic or glass with inert closures are common, and some protocols add a carrier protein or bulking agent to reduce adsorption. Filtration through a sterile filter may be used when a sterile solution is required, but filters can retain peptide if binding occurs. Mixing is usually gentle; vigorous vortexing can introduce air-liquid interfaces that promote aggregation. Each of these steps involves trade-offs between sterility, recovery, and analytical accuracy.
Storage recommendations for reconstituted peptides vary by sequence and intended use, so general rules remain broad. A common laboratory practice is to keep solutions cold, sometimes frozen, and protected from light, but freezing itself can damage certain peptides. The pH of the solution may be adjusted to a range where the peptide is most stable, though changing pH can also alter solubility. Documentation of reconstitution date, solvent, concentration, and storage conditions supports reproducibility. Stability data for a specific peptide are generally established by direct measurement rather than assumed from related compounds.
Once a peptide is in solution, its stability depends on temperature, pH, ionic strength, and the presence of oxygen or light. Many peptides are less stable in liquid form than as dry powders because hydrolysis, oxidation, and aggregation can proceed faster in water. Storage at low temperature slows these reactions but does not eliminate them. Some sequences are particularly sensitive to repeated freezing and thawing, which can cause precipitation or conformational changes. The container material and headspace also influence adsorption and surface-induced aggregation.
Quality control after reconstitution usually includes visual inspection and instrumental analysis. A clear, particle-free solution is generally expected, but color and clarity can vary with sequence and buffer. Chromatographic separation can detect degradation products, while mass confirmation verifies molecular identity. pH measurement and osmolality checks may be relevant for certain applications. Documentation of lot number, solvent, and storage history supports reproducibility and helps distinguish preparation artifacts from sample degradation. Temperature logs and freeze-thaw counts add further context when results are reviewed.
After a peptide solution is prepared, its handling conditions influence how long it remains suitable for use. Solutions are typically separated into small portions to avoid repeated freeze-thaw cycles, which can promote aggregation or precipitation. Containers are chosen to minimize adsorption, especially for peptides that are hydrophobic or present at low concentration. Some laboratories use low-binding plastic tubes or add a carrier protein, although carrier addition can interfere with later analysis. Records usually note the solvent, date, and storage temperature for traceability.
=== Spread of Infection === The apical foramen may serve as a pathway for the spread of infection from the root canal system into the surrounding periapical tissues. When the dental pulp becomes necrotic due to caries or trauma, bacteria may extend through the apical foramen into the periodontal ligament and alveolar bone, potentially triggering apical periodontitis. If left untreated, this development may result in the formation of periapical lesions and abscesses
On the other hand, all neuronal voltage-activated sodium channels inactivate within several milliseconds during strong depolarization, thus making following depolarization impossible until a substantial fraction of sodium channels have returned to their closed state. Although it limits the frequency of firing, the absolute refractory period ensures that the action potential moves in only one direction along an axon. The currents flowing in due to an action potential spread out in both directions along the axon. However, only the unfired part of the axon can respond with an action potential; the part that has just fired is unresponsive until the action potential is safely out of range and cannot restimulate that part. In the usual orthodromic conduction, the action potential propagates from the axon hillock towards the synaptic knobs (the axonal termini); propagation in the opposite direction—known as antidromic conduction—is very rare. However, if a laboratory axon is stimulated in its middle, both halves of the axon are "fresh", i.e., unfired; then two action potentials will be generated, one traveling towards the axon hillock and the other traveling towards the synaptic knobs.
== Function == Members of the ADAM family are cell surface proteins with a unique structure, possessing both potential adhesion and protease domains. Sheddase, a generic name for the ADAM metallopeptidase, functions primarily to cleave membrane proteins at the cellular surface. Once cleaved, the sheddases release soluble ectodomains with an altered location and function. Although a single sheddase may "shed" a variety of substances, multiple sheddases can cleave the same substrate resulting in different consequences. This gene encodes an ADAM family member that cleaves many proteins including TNF-alpha and E-cadherin. ADAM10 (EC#: 3.4.24.81) is a sheddase, and has a broad specificity for peptide hydrolysis reactions. ADAM10 cleaves ephrin, within the ephrin/eph complex, formed between two cell surfaces. When ephrin is freed from the opposing cell, the entire ephrin/eph complex is endocytosed. This shedding in trans had not been previously shown, but may well be involved in other shedding events. In neurons, ADAM10 is the most important enzyme, with α-secretase activity for proteolytic processing of the amyloid precursor protein. ADAM10, along with ADAM17, cleaves the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), to produce soluble TREM2 (sTREM2), which has been proposed as a CSF and sera biomarker of neurodegeneration. ADAM10 belongs to subfamily A, the most ancestral subfamily of ADAM proteins, which is shared by all major groups of animals, choanoflagellates, fungi, and green algae from the class Mamiellophyceae.
=== E-cigarettes === The American Lung Association listed use of flavored e-cigarettes as a risk factor for BO in 2016. Health Canada has, however, seen no cases as of 2023. Public Health England writes that the association has come about as "some flavourings used in e-liquids to provide a buttery flavour contain the chemical diacetyl… However, diacetyl is banned as an ingredient from e-cigarettes and e-liquids in the UK." The UK National Health Service's website states that "vaping does not cause 'popcorn lung'".
Sources: en.wikipedia.org
==== Milestones of 1,500 RBI, 1,500 runs scored and 200 stolen bases (2004) ==== When he hit his sixth career grand slam against Milwaukee on April 9, 2004, Bagwell tied a club record. He recorded his 200th career stolen base on August 30 against Cincinnati to become the tenth player in MLB history to reach that plateau while hitting 400 home runs. On September 18, 2004, Bagwell collected his 1,500th career RBI with a single in the third inning against the Brewers. Two innings later, he homered for his 1,500th run scored, becoming just the 29th player in MLB history and the first Astro to reach both milestones. Bagwell finished with 27 home runs, stopping a streak of eight consecutive seasons with at least 30, but extending a streak of 12 with at least 20. The Astros faced the Braves in the playoffs for the fourth time in Bagwell's career in the 2004 NLDS. In Game 3, on October 7, he hit his first career postseason home run off Mike Hampton in the first inning in a 4–2 extra-inning loss. After three failed attempts to advance past the first round of the playoffs earlier in Bagwell's career, losing to Atlanta in 1997, 1999, and 2001, and seven overall in 43 years of franchise history, the Astros defeated the Braves for their first-ever playoff series win. The quartet dubbed the "Killer B's," this time including Carlos Beltrán and Lance Berkman, ignited the Astros' offense, batting .395 (34-for-86) with eight home runs, 21 RBI and 24 runs scored. The Astros scored an NLDS-record 36 runs in all and Bagwell batted .318 with two home runs and five RBI.
== Veterinary use == Intra-abdominal adhesions are common in rabbits following surgery. Verapamil can be given postoperatively in rabbits which have suffered trauma to abdominal organs to prevent formation of these adhesions. Such effect was not documented in another study with ponies.
In 1999, initiated by the International Olympic Committee to fight against doping in sport, the World Anti-Doping Agency had been founded. After the doping scandal in cycling in the summer 1998 the International Olympic Committee (IOC) decided to establish the WADA to promote, coordinate and monitor the fight of against doping in sport. The headquarters for WADA is in Montreal, Canada. The WADA is the supreme international authority and is allowed to do doping tests and can determine which substances are illegal. In February 2011, the United States Olympic Committee and the Ad Council launched an anti-steroid campaign called Play Asterisk Free aimed at teens. The campaign first launched in 2008 under the name "Don't Be An Asterisk!". In October 2012, the USADA released evidence to corroborate their doping claim against cyclist Lance Armstrong. According to USADA CEO Travis T. Tygart, the evidence against Armstrong includes, "...scientific data and laboratory test results that further prove the use, possession and distribution of performance-enhancing drugs". On 1 November 1989, US Senator Joseph Biden introduced S. 1829, The Steroid Trafficking Act of 1989. The purpose of the act was simple: It would "amend the Controlled Substances Act to further restrict the use of steroids. By designating anabolic steroids as a Schedule II controlled substance, the bill would crack down on illegal steroid use". (Senate Judiciary Committee, 2002, p. 282).
== See also == 2026 state visit by Donald Trump to China 2026 G20 Miami summit China–United States relations List of international trips made by Xi Jinping APEC China 2026 List of international presidential trips made by Donald Trump
The cell counters of that time used LED screens for result review. In 1982, Medonic AB, another Swedish company with focus on hematology, was founded. The founders, Ingemar Berndtsson and Abraham Bottema, both had a long history and experience in hematology, clinical chemistry, and blood banking engineering. In 1985, Medonic AB launched the Cellanalyzer CA 480 system, its first own-developed cell counter with a built-in display that also showed the cell histograms. When computers began to be incorporated into the analyzers, other brands, like the Swelab analyzers, also came with a display. Both targeting the smaller clinical laboratories, Swelab Instrument AB and Medonic AB were competitors on the decentralized hematology testing market. In the late 90s, both Swelab Instrument AB and Medonic AB were acquired by Boule Diagnostics AB. The company has kept the parallel brands and the analyzers are still manufactured from its facilities in Stockholm, Sweden and supplied under the Swelab and Medonic trademarks for the decentralized hematology testing market. When Coulter was acquired by Beckman, former Coulter employees Dr. Harold R Crews, Andrew C Swanson, and Donald Grantham founded Clinical Diagnostic Solutions, Inc. (CDS) in 1997, focusing on the development and production of generic reagents and control material. In 2004, CDS was acquired by Boule. By this acquisition, Boule came to master the skills of the development and production of both instruments and the consumables included in a complete hematology system.
Sources: en.wikipedia.org
=== Speech and sound creation === Sound synthesis, various methods of sound generation in audio electronics Wave field synthesis, a spatial audio rendering technique, characterized by creation of virtual acoustic environments Subtractive synthesis, a method of creating a sound by removing harmonics, characterised by the application of an audio filter to an audio signal Frequency modulation synthesis, a form of audio synthesis where the timbre of a simple waveform is changed by frequency modulating it with a modulating frequency that is also in the audio range Speech synthesis, the artificial production of human speech
From the earliest finds, opium has appeared to have ritual significance, and anthropologists have speculated ancient priests may have used the drug as a proof of healing power. In Egypt, the use of opium was generally restricted to priests, magicians, and warriors. Its invention is credited to Thoth, and it was said to have been given by Isis to Ra as treatment for a headache. A figurine of a goddess dated to around 1300 BC from the Minoan period contains three hairpins shaped as poppy capsules, all of which contain slits that suggest the Cretans knew the method of extracting opium. Additionally, her smile and parting lips suggests that she may be in a state induced by the opium. This has influenced some scholars to call her the "goddess of ecstasy". Further evidence confirms the use of opium in the Mediterranean since the Late Bronze Age due to a number of small lekythi from various places in Crete. These lekythi are supposed to have contained pharmaceutical opium due to the shape of the jars being analogous to those of the poppy head. Additionally, each jar is decorated with vertical stripes that are very similar to the process of cutting into the poppy to extract the sap. There is further evidence for the use of opium during this era due to painted pyxis. These would be decorated with painted poppy capsules and birds holding both poppy capsules and poppy stalks. Opium's use in the ancient Mediterranean world is well written about, with many authors discussing its uses.
Because ODTs are soft in nature, the ability to successfully package an ODT in a bottle is difficult. However, CIMA Labs markets their Durasolv ODT as being able to be placed into bottle for commercial sale, while CIMA's Orasolv is marketed for blisters only. Zydis ODT tablets manufactured by Catalent Pharma Solutions and Lyophilized Freeze drying tablets manufactured by Galien-LPS are delivered in a blister pack. The differences between the two CIMA products are proprietary, however, the primary difference is expected to be the use of microcrystalline cellulose (MCC), such as Avicel PH101, in the Durasolv product. MCC serves multiple purposes in an ODT but in the case of CIMA's products, it acts as a binder, increasing the internal strength of the tablet and making it more robust for packaging in bottles.
The entactogen MDMA is a serotonin releasing agent and, while it also possesses other actions such as concomitant release of norepinephrine and dopamine and weak direct agonism of the serotonin 5-HT2 receptors, its serotonin release plays a key role in its unique entactogenic effects. Entactogens like MDMA should be distinguished from other drugs such as stimulants like amphetamine and psychedelics like LSD, although MDMA itself also has some characteristics of both of these types of agents. Coadministration of selective serotonin reuptake inhibitors (SSRIs), which block the serotonin transporter (SERT) and prevent MDMA from inducing serotonin release, markedly reduce the subjective effects of MDMA, demonstrating the key role of serotonin in the effects of the drug. Serotonin releasing agents like MDMA achieve much greater increases in serotonin levels than SSRIs and have far more robust of subjective effects. Besides MDMA, many other entactogens also exist and are known.
Raw potatoes contain toxic glycoalkaloids, of which the most prevalent are solanine and chaconine. Solanine is found in other plants in the same family, Solanaceae, which includes such plants as deadly nightshade (Atropa belladonna), henbane (Hyoscyamus niger) and tobacco (Nicotiana spp.), as well as food plants like tomato. These compounds, which protect the potato plant from its predators, are especially concentrated in the aerial parts of the plant. The tubers are low in these toxins, unless they are exposed to light, which makes them go green. Exposure to light, physical damage, and age increase glycoalkaloid content within the tuber. Different potato varieties contain different levels of glycoalkaloids. The 'Lenape' variety, released in 1967, was withdrawn in 1970 as it contained high levels of glycoalkaloids. Since then, breeders of new varieties test for this, sometimes discarding an otherwise promising cultivar. Breeders try to keep glycoalkaloid levels below 200 mg/kg (0.0032 oz/lb). However, when these commercial varieties turn green, their solanine concentrations can go well above this limit, with higher levels in the potato's skin.
Sources: en.wikipedia.org
No single time applies to all peptides. Storage life depends on sequence, solvent, concentration, and temperature. Stability should be determined experimentally or taken from supplier data for the specific lot.
Refreezing is possible but repeated cycles are discouraged. Each freeze-thaw step may increase aggregation or loss. Aliquoting before freezing reduces the number of cycles.
Cloudiness, visible particles, color changes, or new peaks in chromatography can indicate degradation. A loss of expected activity in an assay may also suggest a problem. Confirmatory methods include LC-MS and purity analysis.
Lyophilization removes water to produce a dry peptide preparation. Reconstitution adds a solvent back to that preparation to create a liquid solution. The two processes are complementary steps in the lifecycle of many peptide products.